Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (ZBH) is a global innovator in musculoskeletal healthcare, delivering advanced orthopedic solutions for nearly a century. This news hub provides investors and medical professionals with timely updates on product developments, regulatory milestones, and strategic initiatives shaping the future of surgical care.
Track critical updates including quarterly earnings, FDA clearances for robotic surgery systems, and partnerships advancing AI-driven orthopedic solutions. Our curated feed consolidates press releases about joint reconstruction technologies, trauma care innovations, and global market expansions to inform your analysis of this medtech leader.
Discover how Zimmer Biomet’s integration of digital surgery platforms with traditional orthopedic expertise continues to redefine patient outcomes. Bookmark this page for direct access to verified updates about ZBH’s clinical advancements, without promotional commentary or speculative content.
Zimmer Biomet (NYSE: ZBH) has completed the acquisition of Paragon 28, a specialized medical device company in the foot and ankle orthopedic space. The transaction was finalized on April 21, 2025, with Paragon 28 shareholders receiving $13.00 in cash per share plus a contingent value right (CVR) worth up to $1.00 per share based on revenue milestones.
The acquisition strengthens Zimmer Biomet's position in the $5 billion foot and ankle industry, which is experiencing high-single-digit growth. Key benefits include expanding their technology platform, leveraging Paragon 28's specialized sales organization, and accelerating growth in both U.S. and international markets. The deal also enhances opportunities in the Ambulatory Surgery Center (ASC) space.
Following the acquisition, Paragon 28 has become a wholly-owned subsidiary of Zimmer Biomet, and its shares have ceased trading on the NYSE.
Zimmer Biomet (NYSE: ZBH) has scheduled its first quarter 2025 earnings conference call and webcast for Monday, May 5, 2025, at 8:30 a.m. ET. The company will release its quarterly financial results earlier that day at 6:30 a.m. ET.
The earnings call will be accessible through a live audio webcast on the company's Investor Relations website at https://investor.zimmerbiomet.com, with replay availability after the call. For direct dial-in access, U.S. and Canadian participants can call (888) 204-4368, while international callers should use +1 (323) 994-2093, both using conference ID 5103691.
Zimmer Biomet (NYSE: ZBH) has achieved a significant milestone with CE Mark certification for its RibFix Advantage® Fixation System, marking the first CE Mark approval for an intrathoracic rib fixation system. This innovative system is designed for thoracoscopic fixation, stabilization, and fusion of rib fractures through a minimally invasive approach.
The system features a unique Bridge component that auto-contours to reduce fractures and adapts to rib anatomy during tightening, offering potential benefits of reduced soft tissue disruption compared to traditional open reduction internal fixation. Following its success in the US and other markets, the CE Mark approval enables Zimmer Biomet to distribute the system across the European Economic Area (EEA) and other CE Mark-recognizing markets.
Paragon 28 (NYSE: FNA), a specialized foot and ankle orthopedic medical device company, has announced a significant milestone in its pending acquisition by Zimmer Biomet (NYSE: ZBH). The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired, marking a important step in the regulatory approval process.
The transaction still requires additional approvals, including stockholder approval from Paragon 28 and other regulatory clearances. Both companies anticipate the merger to be completed in the first half of 2025, subject to satisfying remaining closing conditions.
Zimmer Biomet (NYSE: ZBH) showcased its diverse orthopedic and musculoskeletal innovations at the AAOS 2025 Annual Meeting in San Diego, March 10-14. The company highlighted its comprehensive hip portfolio, featuring the new Z1™ Triple-Taper Femoral Hip System, alongside latest knee and upper extremity reconstruction technologies.
Key highlights include the newly cleared Persona® Revision SoluTion™ Femur for metal-sensitive patients, and the debut of ZBX™, their new Ambulatory Surgery Center solution. The showcase also featured innovative technologies like the HAMMR® Automated Hip Impaction System, OrthoGrid Hip AI®, HipInsight™ System for mixed reality navigation, and the OsseoFit™ Stemless Shoulder System.
CEO Ivan Tornos emphasized that the company is experiencing one of its largest innovation cycles, positioning Zimmer Biomet at the forefront of customer-centric innovations focused on improving efficiency and patient outcomes.
Zimmer Biomet (NYSE: ZBH) has received FDA 510(k) clearance for its Persona® Revision SoluTion™ Femur, a revolutionary revision knee implant designed for patients with metal sensitivities. The implant is part of the comprehensive Persona Revision Knee System and features a proprietary surface-hardening treatment for enhanced wear performance.
The innovation addresses a significant medical need, as metal hypersensitivity affects 10-15% of the general population and up to 25% of patients with metallic implants. The implant is made exclusively from Tivanium® alloy with the Ti-Nidium Surface Hardening Process, offering an alternative free from common metal allergens like Nickel, Cobalt, and Chromium.
The product will be available commercially in the U.S. in Q3 2025, offering standard and plus sizes to address flexion instability and soft tissue balancing while minimizing implant overhang.
Zimmer Biomet (NYSE and SIX: ZBH) has appointed Kristen Cardillo as Senior Vice President, Chief Communications Officer, effective March 10, 2025. Reporting to President and CEO Ivan Tornos, Cardillo will lead the company's global communications strategy and stakeholder engagement initiatives.
Cardillo joins from 10x Genomics, where she served as Vice President of Corporate Communications. Previously, she held the position of Vice President of Global Communications and Public Relations at Becton, Dickinson and Company (BD), managing internal communications, public relations, social media, and financial communications. Her earlier career includes roles at CareFusion and Cardinal Health. She holds a Bachelor of Science degree in Telecommunications from Ohio University.
Zimmer Biomet (NYSE and SIX: ZBH) has announced its participation in the 27th Annual Barclays Healthcare Conference. The company's management team will deliver a presentation on Thursday, March 13, 2025, at 9:30 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The presentation will be archived for later viewing following the conference.
Zimmer Biomet (NYSE and SIX: ZBH) has appointed Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer, reporting to CEO Ivan Tornos. In his new role, Noor will lead strategy development, oversee M&A activities including the Paragon 28 acquisition integration, and manage research and product development organizations. He will also serve as Chief of Staff to the CEO.
Noor joins from Trivium, where he served as President and Managing Director for Europe, Africa, and Asia, leading transformation initiatives for margin and cash expansion. His previous experience includes serving as CEO of Smiths Medical and roles at Amcor, McKinsey, Ford Motor Company, and Constellation Energy. Noor holds multiple degrees from MIT, including an MS in Product Development and BS degrees in Finance and Mechanical Engineering.
Zimmer Biomet (NYSE: ZBH) has launched the 'You'll Be Back' campaign featuring Arnold Schwarzenegger as Chief Movement Officer. The initiative creates an online community at YoullBeBack.com for people suffering from joint pain, allowing them to share their stories and connect with qualified physicians.
The campaign aims to empower individuals with resources for making informed mobility choices. Selected community members will be featured in a motivational docuseries. According to CDC data, nearly 27 million Americans over 65 are affected by osteoarthritis, the primary cause for joint replacement. By 2030, an estimated 4 million people in the U.S. will need joint replacement procedures.
